News
VIRX
0.8347
-0.19%
-0.0016
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 1d ago
Day One wins FDA nod brain cancer therapy, Ojemda
Day One Biopharmaceuticals’ lead candidate tovorafenib for a type of pediatric brain cancer called low-grade glioma. The treatment branded as Ojemda will be indicated in the U.S. For children with relapsed or refractory pediatric gliomas. XOMA (NASDAQ:XOMA) received a $5M milestone payment after the decision.
Seeking Alpha · 1d ago
Weekly Report: what happened at VIRX last week (0415-0419)?
Weekly Report · 3d ago
Promising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeutics
TipRanks · 04/18 04:28
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
The Travelers Companies, Inc. Shares dipped 8.1% to $205.03 on Wednesday. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. InVO Bioscience shares shot up 256% after the company reported a year-over-year increase in fourth-quarter revenue.
Benzinga · 04/17 17:36
12 Health Care Stocks Moving In Wednesday's Intraday Session
INVO Bioscience stock rose 275.0% to $2.85 during Wednesday's regular session. The company's Q4 earnings report came out yesterday. Vanda Pharma stock moved upwards by 33.33% during the session. Losers include Longeveron (NASDAQ:LGVN) and Dare BiosScience.
Benzinga · 04/17 16:31
Viracta Therapeutics Price Target Maintained With a $13.00/Share by Oppenheimer
Dow Jones · 04/17 12:59
Viracta Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 04/17 12:59
Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target
Benzinga · 04/17 12:49
Analysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)
TipRanks · 04/17 11:50
HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target
Benzinga · 04/16 14:42
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
TipRanks · 04/16 10:30
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Viracta Therapeutics Inc reports topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial. Nana-val demonstrated greater efficacy than nanatinostat monotherapy. The median duration of response continues to mature in the PTCL cohort.
Benzinga · 04/15 16:16
Viracta Therapeutics reports positive results from stage 1 of phase 2 trial for lymphoma treatment
Viracta Therapeutics reports positive results from stage 1 of phase 2 trial for lymphoma treatment. The company has a positive topline results from Stage 1 of the Phase 2 NAVAL-1 trial for T-cell lymphoma. Patients in the Nana-val treatment arm achieved clinically meaningful responses with an overall response rate of 50%.
Seeking Alpha · 04/15 12:40
NXPL, MGRM and OCX among pre-market losers
U.S. Economy NXPL, MGRM and OCX among pre-market losers. Marinus Pharmaceuticals -74% provides update on the phase 3 RAISE trial. NextPlat Corp -19% as FDA puts Phase 1 schizophrenia study on hold.
Seeking Alpha · 04/15 12:21
Viracta Therapeutics Announces Topline Nana-val Results From Stage 1 of the NAVAL-1 Trial In Patients With Relapsed Or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma
Nana-val is a combination of nanatinostat and valganciclovir. Patients in the treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50%. Nana-Val demonstrated substantially greater efficacy than nanatinstat monotherapy.
Benzinga · 04/15 12:02
VIRACTA: NANA-VAL DEMONSTRATED GREATER EFFICACY THAN NANATINOSTAT MONOTHERAPY AND WAS GENERALLY WELL-TOLERATED
Reuters · 04/15 12:00
Weekly Report: what happened at VIRX last week (0408-0412)?
Weekly Report · 04/15 09:25
VIRACTA THERAPEUTICS INC - RECEIVED A WRITTEN NOTICE FROM NASDAQ INFORMING CO THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ'S LISTING RULE
Reuters · 04/09 20:32
More
Webull provides a variety of real-time VIRX stock news. You can receive the latest news about Viracta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.